On May 26, 2026 Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, reported that 37 abstracts have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting. The event will take place May 29 – June 3, 2026 in Chicago, Illinois.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This year’s ASCO (Free ASCO Whitepaper) Annual Meeting marks a significant milestone for Tempus, as we are presenting our largest collection of accepted research to date, further underscoring the critical role that multimodal data and AI-driven insights play in advancing precision medicine across oncology," said Kate Sasser, PhD, Chief Scientific Officer at Tempus. "The breadth of our findings demonstrates the tangible impact of these tools in transforming complex real-world data into actionable evidence, helping more patients benefit from the next generation of innovative therapies."

Research highlights include:

Saturday, May 30, 2026
9:00am – 12:00pm CT

Impact of AI-augmented histopathology review on next-generation sequencing (NGS) success
Poster Board: 536; Abstract Number: 1618

AI-driven RNA-based homologous recombination deficiency algorithm to predict first-line platinum response in metastatic pancreatic cancer.
Poster Board: 193; Abstract Number: 4210

1:30 pm – 4:30 pm CT

ESR1 mutation longitudinal dynamics in RWD cohort of HR+/HER2- metastatic breast cancer patients treated with standard of care hormonal therapy
Poster Board: 199; Abstract Number: 3062

First-line lenvatinib versus dabrafenib plus trametinib (D+T) in BRAF-mutated differentiated thyroid cancer (DTC): Insights from real-world data.
Poster Board: 509; Abstract Number: 6052

Real-world characterization of SEZ6, a transmembrane protein expressed in various solid tumors
Poster Board: 219; Abstract Number: 3082

Sunday, May 31, 2026
9:00am – 12:00pm CT

Multi-center prospective study evaluating an AI-enabled clinical decision support tool to improve early-stage NSCLC biomarker testing
Poster Board: 518; Abstract Number: 8044

Monday, June 1, 2026
9:00 am – 12:00 pm CT

Whole genome sequencing to identify novel, clinically relevant findings missed by standard of care for patients with myelodysplastic syndrome
Poster Board: 363; Abstract Number: 6570

1:30 pm – 4:30 pm CT

GEMINI-BREAST: Evaluating minimal residual disease (MRD) through longitudinal circulating tumor DNA (ctDNA) profiling in breast malignancies
Poster Board: 130b; Abstract Number: TPS649

Explore the full scope of Tempus-authored research and discover how the company is advancing precision medicine at the 2026 ASCO (Free ASCO Whitepaper) Annual Meeting here.

(Press release, Tempus, MAY 26, 2026, View Source [SID1234666073])

On May 26, 2026 Hologic, Inc. and its subsidiary, Biotheranostics, Inc., reported new data demonstrating how the Breast Cancer Index (BCI) Test results influence extended endocrine therapy decisions for patients with early-stage, hormone receptor-positive (HR+) breast cancer. According to the latest analysis, physician recommendations for extended endocrine therapy increased by more than 30% among patients identified by the BCI Test as likely to benefit, while recommendations decreased by nearly 40% for those identified as unlikely to benefit.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The BCI Test is the established test for extended endocrine therapy decision-making, with exclusive guideline recognition from the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) for this purpose. Both classify the BCI Test as the only genomic assay shown to predict who is likely to benefit from extended endocrine therapy beyond five years.2,3

More information on these findings will be presented at the 2026 ASCO (Free ASCO Whitepaper) Annual Meeting on June 1. The data come from a new analysis of the ongoing BCI Registry Study, which evaluates how physicians incorporate prognostic and predictive BCI Test results into real-world treatment decisions.

"Understanding who is likely to benefit from extended endocrine therapy is critical to personalizing care," said Sami Diab, M.D., Medical Director, Oncology at Hologic. "Findings from the BCI Registry Study continue to highlight the real-world impact of the Breast Cancer Index Test in helping physicians make more informed treatment recommendations for their patients."

Detailed findings from the analysis include:

Overall:
The percentage of patients recommended for extended endocrine therapy decreased from 54.6% before BCI testing to 41.2% after BCI testing.
The percentage of patients not recommended for extended endocrine therapy increased from 44.9% before testing to 58% after testing.
Among patients identified by the BCI Test as likely to benefit from extended endocrine therapy (BCI H/I-High):
Physician recommendations for extended endocrine therapy increased from 60.4% before testing to 90.6% after testing.
Among patients identified as unlikely to benefit (BCI H/I-Low):
Recommendations decreased from 51.1% to 11.8%.
"Decisions about extended endocrine therapy are complex, requiring physicians to balance recurrence risk, potential side effects, and clinical and pathologic factors," said Tara B. Sanft, M.D., of Hartford Healthcare and lead author of the study. "Findings from the BCI Registry Study suggest that relying on those factors alone may not provide enough information for physicians and patients to make decisions with confidence. Genomic testing with the Breast Cancer Index Test provides additional insight into tumor biology, helping physicians refine extended endocrine therapy recommendations and better identify which patients are most likely to benefit."

Learn more on June 1, 2026, 1:30-4:30 p.m. CDT at ASCO (Free ASCO Whitepaper) 2026: Impact of the Breast Cancer Index on Extended Endocrine Therapy Recommendations in Patients from the BCI Registry Study1 (Abstract #527/Poster Board #12 — Breast Cancer — Local/Regional/Adjuvant)

About the Breast Cancer Index Test

The Breast Cancer Index Test is a molecular, gene expression-based test uniquely positioned to provide information to help physicians individualize treatment decisions for patients with early-stage, HR+ breast cancer. This breakthrough test helps oncology care teams and patients navigate the difficult trade-offs between taking steps to prevent recurrence of their disease and facing significant side effects and safety challenges related to unnecessary treatment.

The Breast Cancer Index Test has guideline designation from the American Joint Committee on Cancer for cancer staging based on molecular profile. The ASCO (Free ASCO Whitepaper) Clinical Practice Guideline and the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) acknowledge the Breast Cancer Index Test as a biomarker to help inform extended endocrine treatment decisions.2,3

The Breast Cancer Index Test is intended for routine clinical use, and physician treatment decisions based on results are the responsibility of the physician. It is a sole-source laboratory-developed test (LDT) performed by Biotheranostics, Inc., a CLIA-certified and CAP-accredited diagnostic laboratory. It has not been cleared or approved by the U.S. Food and Drug Administration. For more information, visit www.breastcancerindex.com.

(Press release, Hologic, MAY 26, 2026, View Source [SID1234666072])

On May 26, 2026 Median Technologies (FR0011049824, ALMDT, "Median" or the "Company"), manufacturer of eyonis, a suite of artificial intelligence (AI) powered Software as Medical Devices (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, reported that the Company will be participating in the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting taking place from May 29 to June 2, McCormick Place, Chicago, IL, USA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Median’s team will be hosting interested parties at booth #36102, South Building, Hall A, McCormick Place, from May 30 to June 1 (exhibit dates), from 9:00 am to 5:00 pm CT, where it will share the most recent advances for its central and AI-powered imaging services for oncology clinical trials.

Median will host two presentation sessions on how the Company’s new solutions for radiopharmaceutical image processing and cachexia assessment are advancing oncology research. Sessions will take place at booth #36102.

Unlocking Oncology Trial Potential with Radiopharmaceutical Imaging – Saturday, May 30th | 11:30 AM – 12:00 PM | Presenter: Antoine Iannessi, VP Medical Affairs iCRO
Advancing Cachexia Assessment in Oncology Trials with Body Composition Analysis – Sunday, May 31st | 11:30 AM – 12:00 PM | Presenter: Antoine Iannessi, VP Medical Affairs iCRO
The ASCO (Free ASCO Whitepaper) Annual Meeting is the world’s premier oncology conference, organized by the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), the largest oncology society in the world. Each year, the ASCO (Free ASCO Whitepaper) conference brings together more than 35,000 oncologists from all around the globe, and is attended by all medical, educational and industrial stakeholders involved in the field of oncology worldwide. More about the ASCO (Free ASCO Whitepaper) Annual Meeting: View Source

(Press release, MEDIAN Technologies, MAY 26, 2026, View Source [SID1234666071])

On May 26, 2026 IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, reported its participation in the following events at the 2026 Jefferies Global Healthcare Conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2026 Jefferies Global Healthcare Conference
Wednesday, June 3rd, 2026 at 7:35 AM ET

Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Maury Raycroft, Ph.D. Equity Research Analyst, Biotechnology
AI Panel at the 2026 Jefferies Global Healthcare Conference
Thursday, June 4th, 2026 from 8:45 AM ET

Panel discussion featuring Yujiro S. Hata, President and Chief Executive Officer, moderated by Akash Tewari, Global Head of Biopharmaceutical Research
A live audio webcast of the conference events, as permitted by the conference host, will be available under the "Investors/Events" section of the IDEAYA website at View Source and/or through the conference host. A replay of the webcasts will be accessible for 30 days following the live event.

(Press release, Ideaya Biosciences, MAY 26, 2026, View Source [SID1234666070])

On May 26, 2026 Akeso, Inc. (9926.HK) ("Akeso" or the "Company") reported that more than 40 clinical studies of its oncology portfolio will be presented at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place May 29 – June 2 in Chicago, Illinois. Notably, the presentations include one Late-Breaking Abstract (LBA) selected for the prestigious Plenary Session, alongside four Oral or Rapid Oral presentations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The datasets featured at ASCO (Free ASCO Whitepaper) 2026 primarily highlight the Company’s core first-in-class bispecific antibodies — cadonilimab (PD-1/CTLA-4) and ivonescimab (PD-1/VEGF) — along with other novel therapeutic antibodies such as ligufalimab, a next-generation CD47 monoclonal antibody. These presentations include several potentially practice-changing datasets across multiple tumor types.

A pivotal highlight will be the Phase III overall survival (OS) results from the HARMONi-6 study, evaluating the survival advantage of ivonescimab combined with chemotherapy versus a PD-1 inhibitor combined with chemotherapy in the first-line setting for advanced squamous non-small cell lung cancer (sq-NSCLC). Additional notable presentations feature ivonescimab in small-cell lung cancer (SCLC) that has progressed after first-line chemoimmunotherapy, ivonescimab plus chemotherapy in first-line metastatic colorectal cancer (mCRC) from a global Phase II interim analysis, alongside cadonilimab-based regimens in renal cell carcinoma, melanoma, colorectal cancer, head and neck cancer, gynecologic malignancies, and biliary tract cancer.

The maturity and breadth of these datasets underscore the success of Akeso’s innovation engine, demonstrating the clinical benefits of the Company’s differentiated bispecific antibody platform to the international oncology community.

Key Presentations

Plenary Session

Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non-small cell lung cancer: Overall survival results of the Phase 3 HARMONi-6 study

Abstract: LBA4
Session: Plenary Session
Date/Time (CDT): May 31, 2026, 2:47 PM–2:59 PM
Presenter: Professor Shun Lu, Shanghai Chest Hospital
Oral Presentation

Efficacy and safety of ivonescimab combined with liposomal irinotecan in patients with small-cell lung cancer (SCLC) progressing after first-line chemoimmunotherapy: A multicenter, Phase 2 study

Abstract: 8007
Date: June 2, 2026
Presenter: Professor Yun Fan, Zhejiang Cancer Hospital
Oral Presentation

A prospective, multicenter, Phase Ib/II trial of first-line cadonilimab plus axitinib in advanced non–clear cell renal cell carcinoma

Abstract: 4501
Date: June 2, 2026
Presenter: Dr. Junru Chen, West China Hospital, Sichuan University
Rapid Oral Presentation

Neoadjuvant ivonescimab (AK112, a PD-1/VEGF bispecific antibody) combined with nab-paclitaxel and cisplatin for resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC): An exploratory Phase II study

Abstract: 6014
Date: June 2, 2026
Presenter: Professor Kunyu Yang, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Rapid Oral Presentation

Cadonilimab or ivonescimab plus axitinib in metastatic mucosal melanoma: Results from a Phase Ib trial

Abstract: 9516
Date: May 31, 2026
Presenter: Professor Lili Mao, Peking University Cancer Hospital
International Multicenter Phase II Study

Ivonescimab (ivo) with oxaliplatin + fluorouracil (5-FU) + leucovorin calcium (mFOLFOX6) for patients (pts) with unresectable metastatic colorectal cancer (mCRC): A phase II study

Abstract: 3576
Date: May 30, 2026
First Author: David Berz, MD, PhD, Department of Oncology, Valkyrie Clinical Trials, Inc

(Press release, Akeso Biopharma, MAY 26, 2026, View Source [SID1234666069])